Strategic Partners

Strategic partnerships are an important part of our business strategy to create value for investors and patients.

Catalyst and ISU Abxis, a leading Korean biopharmaceutical company (086890.KQ-KOSDAQ), formed a strategic collaboration in 2013 to advance the development and commercialization of Catalyst's next-generation Factor IX development candidate, CB 2679d/ISU304 for the prevention and treatment of bleeding in individuals with hemophilia B. The collaboration has been focused on advancing CB 2679d/ISU304 through IND-enabling preclinical development and Phase 1/2 clinical development in individuals with hemophilia B. Preclinical development has been completed and ISU commenced the Phase 1/2 clinical trial in June 2017.

Catalyst is entitled to up front and milestone payments and has retained worldwide commercialization rights, except for ISU Abxis’ right of first refusal for commercialization rights in Korea, and subject to a future profit sharing arrangement.